Stifel Maintains Buy on Janux Therapeutics, Lowers Price Target to $38

Benzinga · 12/02/2025 17:09
Stifel analyst Bradley Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $46 to $38.